Mentioned:
Psychedelic assisted therapies are getting closer than ever in the United States of America. Which is exactly why Cybin is making new moves to expand clinical access.
What’s happening:
- Cybin (NYSE: CYBN) has announced a new partnership with clinical technology company Osmind to accelerate commercial preparations for their novel psychedelic therapeutics
Why it matters:
- Osmind has one of the largest networks of clinics for interventional psychiatry in the United States of America, with more than 800 operating clinics currently using their technology and electronic health records platform
Going deeper:
- The new partnership between Osmind and Cybin is focused on preparing for Cybin’s eventual commercial launch in America and providing easy clinical access for patients who are prescribed psychedelic assisted therapy
- Cybin is one of the most advanced publicly traded psychedelic drug development companies in the world, with their novel molecule CYB003 currently in Phase III trials for treating major depressive disorder
The fine print:
- Cybin has still not received official approval from the United States Food and Drug Administration for CYB003 and will not be able to dose patients in a clinical setting until receiving official regulatory approval
